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ABSTRACT
Introduction: Cigarette smoke contributes to a diverse
range of diseases including chronic obstructive
pulmonary disease (COPD), cardiovascular disorders
and many cancers. There currently is a need for
human challenge models, to assess the acute effects of
a controlled cigarette smoke stimulus, followed by
serial sampling of blood and respiratory tissue for
advanced molecular profiling. We employ precision
sampling of nasal mucosal lining fluid by absorption to
permit soluble mediators measurement in eluates.
Serial nasal curettage was used for transcriptomic
analysis of mucosal tissue.
Methods and analysis: Three groups of strictly
defined patients will be studied: 12 smokers with
COPD (GOLD Stage 2) with emphysema, 12 matched
smokers with normal lung function and no evidence of
emphysema, and 12 matched never smokers with
normal spirometry. Patients in the smoking groups are
current smokers, and will be given full support to stop
smoking immediately after this study. In giving a
controlled cigarette smoke stimulus, all patients will
have abstained from smoking for 12 h, and will smoke
two cigarettes with expiration through the nose in a
ventilated chamber. Before and after inhalation of
cigarette smoke, a series of samples will be taken from
the blood, nasal mucosal lining fluid and nasal tissue
by curettage. Analysis of plasma nicotine and
metabolites in relation to levels of soluble inflammatory
mediators in nasal lining fluid and blood, as well as
assessing nasal transcriptomics, ex vivo blood platelet
aggregation and leucocyte responses to toll-like
receptor agonists will be undertaken.
Implications: Development of acute cigarette smoke
challenge models has promise for the study of
molecular effects of smoking in a range of pathological
processes.
Ethics and dissemination: This study was approved
by the West London National Research Ethics
Committee (12/LO/1101). The study findings will be
presented at conferences and will be reported in peer-
reviewed journals.
BACKGROUND
There are profound causative and contribu-
tory effects of chronic cigarette smoking in a
range of disease processes, as well as consider-
able mortality.1 2 In order to understand the
changes in the lungs due to chronic smoking,
it is relevant to assess the immunological
responses to acute smoke exposure. Repetitive
acute effects of cigarette smoke in susceptible
individuals may lead to cumulative irreversible
damage.3 Despite cigarette smoking being the
Strengths and limitations of the study
▪ This model involves limited numbers of highly
selected individuals, and as such selection bias
will inevitably occur. However, in conjunction
with serial sampling in controlled conditions,
this enables discrimination of relatively small
changes in levels of cigarette smoke constituents
and the subsequent inflammatory response.
▪ It is possible to study acute effects of cigarette
smoke in a variety of smoking-related diseases.
In this way it may be possible to gain molecular
insight into the pathology of chronic obstructive
pulmonary disease, cardiovascular disease and
neoplasia.
▪ The specific categorisation of patients with
notable emphysema, who are not currently
taking any anti-inflammatory or disease modify-
ing interventions, will help reveal target pathway
nuances that drive oxidant-dependent chronic
disease.
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most important risk factor for the development of chronic
obstructive pulmonary disease (COPD) and a major con-
tributory influence in the development of cardiovascular
disease, the use of human cigarette challenge models has
been underutilised in the investigation of immune and
local influences on the disease.4 This is somewhat surpris-
ing, as we still know little about the mechanisms involved
in smoke-induced inflammation in man.
While several downstream effects of cigarette smoking
are common to all smokers, such as antioxidant gene acti-
vation and aryl hydrocarbon signalling, it is estimated
that only 13–50% of smokers actually develop COPD,5 6
and within this group, there is great clinical heterogen-
eity.2 The immunopathology of COPD is complex and
variable, involving the large airways (bronchitis), small
airways (bronchiolitis), lung interstitium (emphysema
and interstitial lung disease), pulmonary vasculature
(pulmonary artery hypertension) and systemic and car-
diovascular complications.7 There is also the added com-
plexity attributable to the innate immune response to
oxidants and microbes.8 9 Our group and others have
previously demonstrated that cigarette smoke (extract)
can activate human immune and respiratory epithelial
cells in vitro leading to the release of the proinflamma-
tory chemokine CXCL8.10–15 In addition, following
smoking, blood of smokers is ‘primed’ to activation ex
vivo by pathogen-associated molecular patterns (PAMPs)
including lipopolysaccharide (LPS).16 Most recently we
have performed a pilot transcriptomic study using
human monocytes stimulated in vitro and shown that
smoke activates and inhibits discrete groups of genes
involved in oxidant stress and inflammation.17 In add-
ition there have been individual genomic, transcriptomic
and metabolomic studies in cell-based18–24 and animal
models25 of smoking which have further defined the role
of cigarette smoke as an inflammatory insult. However,
there is now a need for a multisystems-based approach in
man in vivo to truly advance our understanding of how
cigarette smoking induces inflammation.26
A protocol for a study of the effects of smoking in
patients with COPD has recently been reported by Lo
Tam Loi et al27 from Utrecht, Netherlands. This group
proposes the assessment of acute effects of smoking at
5 min after smoking three cigarettes, at 2 h, 24 h and
after a 6 week interval. They also propose assessment of
cross-sectional inflammatory responses in different
patient groups. In this study sampling from patients con-
sists of blood, sputum and exhaled breath condensate
(EBC); and they employ endobronchial sampling for
biopsy, epithelial lining fluid and epithelial brushings.
Our group is currently conducting an in vivo model of
acute cigarette smoke inhalation challenge in smokers
with COPD and appropriate controls. Our study differs
in selection of patients, and having more defined condi-
tions for cigarette smoke exposure. In addition, we have
an intensive sampling schedule over the 5 h following a
controlled cigarette smoke stimulus, with a focus on
blood and nasal non-invasive sampling, during which we
assess levels of nicotine and metabolites in relation to
proinflammatory effects. Such a study has thus far been
difficult since access to human airway tissue and secre-
tion samples in a minimally invasive serial manner has
not previously been possible.
There has been recent progress in finding novel bio-
markers for COPD,28 29 and a focus on recognising new
phenotypes of COPD.30 GlaxoSmithKline has completed
a 3-year longitudinal study in 2180 patients with COPD
entitled ECLIPSE (Evaluation of COPD Longitudinally
to Identify Predictive Surrogate Endpoints).31 In terms
of the natural history of COPD it was found that sputum
neutrophil counts32 and EBC pH was not useful.33 EBC
has limitations of dilution and salivary contamination.34
In contrast, induced sputum contains many dead and
dying cells, making quantitation of levels of inflamma-
tory mediators problematic.
The nasal epithelium is the first point in the respira-
tory system where cigarette smoke has contact with the
respiratory mucosa. As part of ‘the one airway concept’
that is well established in asthma, there is also consider-
able evidence for nasal involvement in COPD.35 36
Patients with COPD have chronic nasal symptoms and
impaired quality of life,37–39 with upper and lower airway
inflammation,40 and exacerbation of COPD is associated
with increased pan-airway inflammation.41 In addition,
young ‘healthy smokers’ have functional and inflamma-
tory changes in the nose and lower airways.42
For this reason our study is based on taking respiratory
samples from the nose by nasal absorption and curet-
tage. It has long been recognised that there is ‘one
airway’, with a strong functional and immunological rela-
tionship between the nose and the bronchi.43–45 Patients
with respiratory disease commonly have inflammation of
the airways and nasal passages, with a similar inflamma-
tory infiltrate in the lower and upper airways. It is now
possible to obtain repeated samples of nasal exudates
before and after nasal challenge in a relatively non-
invasive manner by techniques employing strips of nasal
synthetic absorptive matrix (SAM) inserted into the
nostril in the technique of nasosorption. Our experience
with SAM for nasosorption has been published with
regard to cytokines and chemokines in children with
allergic rhinitis,46 infants with a family history of atopy,47
and in atopic adults after nasal allergen challenge.48 In
addition, nasal epithelial curettage employing the
Rhinoprobe device is useful to obtain a pinhead of
mucosal tissue, in a technique that does not require
local anaesthesia.49 This approach has the advantages of
being safe and comfortable for the patient, yet providing
high-quality samples for transcriptomic analysis.
It is well documented that cigarette smoke is a
complex stimulus with a variety of acute and chronic
effects reported in the literature. We set out to design a
study to map the acute inflammatory response to smoke
in the human respiratory system and circulating cells,
with a view to providing a comprehensive molecular sig-
nature of smoking-related events in COPD. We believe
2 Ross CL, et al. BMJ Open 2015;5:e005750. doi:10.1136/bmjopen-2014-005750
Open Access
that our model of cigarette smoke exposure comple-
ments the clinical research model of Lo Tam Loi et al.27
These approaches should lead to advances within the
field of assessment of smoking-related immunopathol-
ogy; therefore we have taken this opportunity to share
our rationale and protocol.
Aims of the study
Our study uses non-invasive techniques for sampling, to
which ‘omic’ technology will be utilised for the compre-
hensive characterisation of this complex multifaceted
disease, with the aim of identifying disease-dependent
whole system responses to acute cigarette smoke chal-
lenge.50 The transcriptomic analysis in this study has
been designed to examine changes in gene expression
under the specific physiological condition of acute cigar-
ette smoking. This may in future allow for early interven-
tion in populations exhibiting similar gene expression
profiles to those observed in established COPD. This
approach also provides a diagnostic profile of patients so
that treatment can be targeted and personalised.
Theoretically, it may be possible to subclassify COPD
populations, who phenotypically appear similar. In add-
ition, there is a need to analyse products of these genes,
given that transcriptomic analysis does not solely
account for the diversity in protein production and cel-
lular metabolites. A range of cytokines will be measured
before and after an acute cigarette challenge to identify
biomarkers and cell-signalling pathways associated with
COPD. Metabolic profiling will be used to detect the
physiological changes induced by a cigarette challenge.
Metabolic signatures may provide prognostic, diagnostic
and surrogate markers for COPD, and identify simple
non-invasive markers of drug responses for future ther-
apies.51 These investigations will be carried out on nasal
lining fluid, nasal curettage, and blood, to analyse local
and systemic changes over a 5 h period following a two
cigarette challenge. Finally, it has been suggested that
patients with stable COPD have increased platelet
reactivity including circulating platelet-monocyte aggre-
gates,52 therefore, potential cardiovascular effects will
also be assessed by measuring platelet aggregation in
these patients.
Primary objective
To develop a novel cigarette challenge in vivo model
incorporating full network biology analysis of transcrip-
tomic, metabolomic and cytokine/chemokine changes
in the nose and blood of smokers with Global Initiative
for Chronic Obstructive Lung Disease (GOLD, http://
www.goldcopd.org) Stage 2 COPD, healthy smokers with
normal lung function and non-smokers, post-cigarette or
post-sham/dummy cigarette challenge.
Secondary objectives
1. To stimulate blood of smokers with GOLD Stage 2
COPD16 healthy smokers and non-smokers ex vivo
with interleukin-1β (IL-1β) and PAMPs.
2. To identify molecular biomarkers for patients with
COPD: to assist in defining novel therapeutic targets,
to better stratify phenotypes and to facilitate monitor-
ing of patients.
3. To develop a cigarette smoking challenge model in
patients with COPD with an aim to utilise this in
therapeutic trials of novel therapeutic agents.
4. To carry out platelet aggregometry following stimula-
tion with specific agonists, with the aim of understand-
ing the associated pathophysiology of thrombosis and
the pharmacology of respective therapies.
METHODS
Study populations
This is a parallel group study in three groups of 12 age,
sex, ethnicity, smoking history and body mass index
matched patients (table 1):
▸ Group 1: Smokers with moderate COPD (GOLD
Stage 2);
▸ Group 2: Healthy smokers with normal lung function
(no evidence of COPD);
▸ Group 3: Healthy individuals who have never smoked.
Smokers will be current smokers, smoking at least five
cigarettes a day, with a minimum pack year history of
10 years. Current cannabis smokers or smokers with a
history of moderate or heavy cannabis use will be
excluded from the study. Non-smokers must not have
smoked a single cigarette in the 12 months prior to the
study, and must have smoked less than 100 cigarettes in
their lifetime.
Cigarette smoke challenge procedure
One to three screening visits may be required to complete
spirometry (and full lung function with gas transfer for
carbon monoxide (TLCO) in smokers), 5 slice high-
resolution CT (in smokers only) as well as laboratory safety
tests, urinalysis, ECG and physical examination.
On the cigarette challenge day, all patients will be
required to attend our unit at 9:00. They must have
fasted and refrained from smoking from 21:00 on
evening prior to the scheduled challenge. Following
baseline investigations, smokers in groups 1 and 2 will
smoke two cigarettes back to back, in a controlled envir-
onment, exhaling the smoke via their nostrils, while
non-smokers carry out normal tidal breathing over a
10 min period (figure 1).
Schedule of sampling
All patients will have nasal epithelial curettage and naso-
sorption procedures with serial blood samples (figures 2
and 3). Serial nicotine and cotinine levels will also be
taken to plot the relative smoke exposure of each indi-
vidual, as well as providing an objective measure of their
baseline smoking habit and clearance of nicotine from
their system. Full blood counts and clotting studies will
also be performed during the study to ensure patients
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Table 1 Summary of inclusion criteria and assessments in the acute cigarette smoke challenge
Inclusion criteria
Sample and assessment
parameters References
General criteria for 3 groups of patients, each of 12
individuals
▸ 45–75 years old
▸ Good general health, with no chronic illnesses
▸ No prescribed anti-inflammatory medications
(including statins)
▸ Females of childbearing potential have a negative
pregnancy test
PlasmaCigarette smoke
Correlates of exposure
▸ Nicotine
▸ Cotinine
▸ 3-Hydroxycotinine
Plasma mediators
▸ Prostanoids
▸ Metabolites
▸ Cytokines and chemokines
Whole blood ex vivo
▸ Transcriptomics
▸ TLR-agonist stimulation of
leukocytes
▸ Platelet aggregation
Nicotine54
Serum cytokines29 55–59
Serum metabolites60–62
Blood ex vivo
stimulation16 17
Smokers
▸ Current: ≥5 cigarettes/day
▸ History: ≥10 pack years
Non-Smokers
▸ Have never smoked
Nasosorption (SAM)
▸ Prostanoids: LTB4, LTC4, PGD2
▸ Metabolites
▸ Cytokines and chemokines
Group 1: Smokers with GOLD Stage 2 COPD
▸ Post-bronchodilator FEV1 50–79%; Forced expiratory
ratio <70%
▸ TLCO of <80% of normal
▸ Emphysema on 5 slice HRCT of the chest
Nasal curette
▸ Immunohistology
▸ Transcriptomics
▸ Flow cytometry
Epithelial culture
Group 2: Healthy smokers
▸ Post-bronchodilator FEV1 ≥80%; Forced expiratory
ratio ≥70%
▸ TLCO ≥80% of normal
▸ Normal 5 slice HRCT of the chest
EBC EBC33 63
Group 3: Healthy non-smokers
▸ Post-bronchodilator FEV1 ≥80%; Forced expiratory
ratio ≥70%
▸ TLCO and HRCT not done
Sputum Sputum32 64 65
COPD, chronic obstructive pulmonary disease; EBC, exhaled breath condensate; FEV1, forced expiratory volume in one second; HRCT,
high-resolution CT; SAM, synthetic absorptive matrix; TLR, toll-like receptor.
Figure 1 Cigarette smoke
challenge model (HEPA,
high-efficiency particulate air).
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have not developed any biochemically relevant illnesses
or clotting abnormalities.
Analytical methods
A representative range of non-invasive sampling methods
with associated analytical parameters is shown in table 1.
Nicotine/cotinine
Nicotine, cotinine and 3-hydroxy-cotinine will be mea-
sured in serum over the whole time course. Analysis by
capillary gas chromatography will be carried out by
Advanced Bioanalytical Service Laboratories (Welwyn
Garden City, UK).
8-Isoprostane enzyme immunoassay
Measurement of 8-isoprostane will be carried out in
both serum and nasoabsorption fluid at all time points
using an 8-isoprostane enzyme immunoassay (EIA) kit
(Cayman Chemicals, Ann Arbor, Michigan, USA).
Metabolomics
In view of the multiple factors that can influence metabol-
ism, all patients are required to fast for 12 h before the
challenge begins; during this time they may only consume
water. Metabolomic profiling, to be conducted by
Metabolon (North Carolina, USA), measures an extensive
range of metabolites (<1000 Da) in plasma and nasal
Figure 2 Schedule of assessments (SAM, synthetic absorptive matrix, TLR, toll-like receptor).
Figure 3 Nasal sampling
methods (SAM, synthetic
absorptive matrix).
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lining fluid after cigarette smoke. Metabolomic analysis will
include amino acids, carbohydrates, lipids, nucleic acids
and cofactors, molecules of redox homeostasis (eg, gluta-
thione), organic acids, and small peptides. Importantly,
many of the catabolites or biosynthetic intermediates of
these metabolites are also detected, assisting in elucidating
underlying mechanistic insight. Blood and nasoabsorption
samples will be taken at time points listed in figure 2.
Transcriptomics
Two nasal epithelial curettage samples will be taken using
a Rhinprobe prechallenge and at 300 min postchallenge.
RNA will be extracted using TRIzol (Invitrogen, Paisley,
UK). Blood will be taken at prechallenge, 20 and 300 min
postchallenge with RNA extracted using the PAXgene
Blood RNA extraction kit (PreAnalytiX GmbH,
Hombrechtikon, Switzerland). RNA will be run on an
Illumina HT12 V.4 (RefSeq Build 38 Rel 22) chip
(Illumina, San Diego, USA) with analysis carried out using
a dedicated array analysis programme GeneSpring GX
11.3 of all genes. Genes which have changed significantly
will be identified using unpaired t tests (p<0.05) with
Benjamini-Hochberg false discovery rate correction.
Genes will be reported as 1.2-fold, 1.5-fold and twofold
increases. Quality and assessment of global transcriptome
changes will be assessed using principle component ana-
lysis in GeneSpring. Genes that have changed significantly
will also be further explored using a dedicated pathway
analysis tool (Ingenuity Systems Pathway Analysis software,
IPA) techniques.
Ex vivo peripheral whole blood stimulation
Stimulation of whole blood taken prechallenge and at 20
and 300 min postchallenge will be performed using a
range of toll-like receptor (TLR) agonists to obtain a 24 h
dose response curve of the following ligands: LPS
(TLR4), FSL-1 (TLR6/2), Pam3CSK4 (TLR1/2), Poly(I:C)
(TLR3) and IL-1β (Invivogen, San Diego, USA). Serum
will then be removed and subsequently measured
for CXCL8 and IL-1β by ELISA (R&D Systems,
Abingdon, UK).
Platelet aggregation
For platelet aggregation studies, blood will be collected
prechallenge and at 20 and 300 min postchallenge.
Platelet rich plasma will be aliquoted into individual
wells of half-area 96-well plates coated with gelatin and
one of seven concentrations of arachidonic acid, ADP,
collagen, epinephrine, ristocetin, TRAP-6 amide or
U46619. Platelet aggregation will be determined by
changes in light absorbance, and release of thromb-
oxane (TX)A2 by ELISA.
Homogeneous time resolved fluorescence assay
Serum and nasoabsorption fluid will be screened, across
all time points, for prostaglandin E2 and leukotriene B4
levels using the homogeneous time resolved fluorescence
(HTRF) assay kits from Cisbio Assays (Bedford, MA).
Chemokine/cytokine immunoassay
Using a Meso Scale Discovery (MSD) immunoassay
system (MSD, Maryland, USA), a variety of chemokines,
cytokines and vascular markers will be measured in
blood and nasoabsorption samples at the time points list
above.
Statistical analyses
This is an exploratory clinical study, and we are aware
that there may not be detectable differences between
groups based on measurement of particular parameters
and the size of effects.
DISCUSSION
Clinical challenge models have been fundamental to clin-
ical research in asthma: employing inhalation of agents
such as methacholine, histamine, AMP, allergens and
occupational agents such as isocyanate and ozone. In con-
trast there has been little clinical research on the effects of
cigarette smoke in vivo involving patient studies, despite
this being the known causative agent in COPD.
Development of clinical challenge models that involve cig-
arette smoke thus have relevance to studying respiratory,
cardiovascular and neoplastic effects of cigarette smoke.
The major consideration in developing a cigarette
smoke challenge model is the ethical aspect of not encour-
aging a smoker to continue smoking, and ensuring that
maximal support is given to the individual to stop smoking
(table 2). Furthermore, we are studying patients with
mild–moderate disease, in whom there may be the possi-
bility of smoking cessation before permanent disability sets
in. Other studies have tended to evaluate later stage
disease, by which time smoking cessation has less benefi-
cial effects in terms of lung function.53
A secondary consideration is ensuring the well-being
of the scientific and clinical staff involved in the study,
and minimising exposure to cigarette smoke. In our
study design, all smokers will be established in the habit
and will be actively encouraged to enter into a smoking
cessation programme immediately following their cigar-
ette challenge. Our unit has adapted a body plethysmo-
graphy box, with the addition of a carbon filter and
high-efficiency particulate air filter, in order to ensure
staff are not exposed to the harmful effects of smoke. If
patients were to receive their cigarette challenge outside
of the hospital, there may be confounding effects of
additional pollutants, temperature and exercise.
An important feature of the study is that smoking two
cigarettes is physiologically relevant as a challenge, and
that we were able to document levels of nicotine and
metabolites over a 5 h period. We adopted this aspect of
the study having considered the design of pharmacoki-
netic studies with nicotine delivery devices. We intend to
standardise the technique of smoking by giving two
Marlboro Red cigarettes, noting the total number of
inhalations and encouraging exhalation through the
nose. Controlled smoke exposure enables accurate
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assessment of patients’ smoking exposure by measuring
concomitant nicotine and cotinine levels. The majority
of studies do not mandate any particular smoking
restrictions prior to sampling. In this study it may be pos-
sible to formally compare nicotine exposure with levels
of induced biomarkers.
A key feature of our acute cigarette smoke challenge
model involves fasting and refraining from smoking for
12 h before and 5 h after having a controlled cigarette
smoke exposure. We also ensure that patients are not
taking any medication that may interfere with responses.
This abstinence is necessary due to the extreme sensitivity
of measurements such as metabolomics. Metabolomics
involves assessment of levels of small molecules and will
include molecules such as dietary constituents and drugs.
We take serial blood and nasal samples, in a manner
similar to a phase I pharmacokinetic study of exposure to
a single dose of drug.
The proposed study involves precision nasal sampling.
This is non-invasive, and has potential for point-of-care,
bedside and clinic monitoring. In contrast, bronchoscopy
is a research procedure only undertaken with great care in
patients with COPD. Hence, non-invasive sampling offers
great potential for future use of the model in further obser-
vational and drug studies. In contrast to many studies
looking at gene expression in cross-sectional populations of
smokers, our model has the benefit of acquiring samples
longitudinally before and after a challenge with a known
trigger of the disease. This increases the power to detect
effects of the cigarette smoke challenge. We will thoroughly
evaluate the acute response to cigarettes with 10 blood and
nasal sampling time points within a 5 h challenge period.
Figure 4 Human integrated
iterative inflammometry (CVS,
cardiovascular system; TLR,
toll-like receptor; PAMPs,
pathogen-associated molecular
patterns).
Table 2 Features and ethical issues with the acute cigarette smoke challenge
Features of the model Ethical issues
Advantages
▸ Human model
▸ Acute-on-chronic inflammation
▸ Serial non-invasive sampling
▸ Combined direct measurement of biomarkers
and ex vivo stimulation
▸ Limited numbers of strictly defined patients
▸ Compare with in vivo animal models
All patients must be advised to stop smoking, and offered full clinical,
psychological and pharmacological support to carry this out
There must be no encouragement for the patient to begin or continue
smoking
Some frail patients with COPD will have difficulty fasting and refraining
from cigarettes for the morning
Clinical disease detected through the investigations must be fully
treated, regardless of participation in the study
Disadvantages
▸ Difficulty recruiting a small number of highly
defined patients
▸ Need to validate upper versus lower airway
inflammation, including tissue biopsies
▸ Signal parameters must reliably change after
acute cigarette smoke exposure
▸ Lung function and CT changes may occur after
acute smoke exposure
Some frail patients with COPD will have difficulty fasting and refraining
from cigarettes for the morning
The patient should not be taking any anti-inflammatory or confounding
therapy: therapy must not be withheld
COPD, chronic obstructive pulmonary disease.
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Given the heterogeneity of the disease and the fact
that patients with significant comorbidities (such as car-
diovascular disease) are excluded, we are likely to be
evaluating a subpopulation of patients with mild COPD.
This is inevitable in any COPD study, but worth noting,
as it may be that this group behaves differently to those
with comorbidities.
The setting up of such studies, using a fully integrated
approach that incorporates network biology, where sam-
pling occurs after the administration of causative factors
will help us better understand the disease and design
more robust clinical trials. This type of approach is illu-
strated in figure 4 has a far ranging applications to a
number of chronic inflammatory diseases.
Author affiliations
1Imperial Clinical Respiratory Research Unit (ICRRU) and Biomedical
Research Centre (BMRC), Centre for Respiratory Infection (CRI), St Mary’s
Hospital, Imperial College, London, UK
2National Heart and Lung Institute, Imperial College, London, UK
3William Harvey Research Institute, Barts and The London, Queen Mary’s
School of Medicine and Dentistry, London, UK
4Sunovion Pharmaceuticals Europe Ltd. (Sunovion Europe), London, UK
5Dainippon Sumitomo Pharma Co Ltd, Osaka, Japan
6Department of Molecular Regulation for intractable Diseases, Institute of
Medical Science, Tokyo Medical University, Tokyo, Japan
Contributors CLR contributed to designing the clinical aspect of the study and
writing the manuscript. NG-P contributed to the ethics submission and design
of laboratory-based methods for the protocol. PCA contributed to the design of
the platelet protocols, ethics submission and writing the manuscript. JAM
contributed to the writing of the manuscript and design of the overall study.
TDW contributed to the design of the platelet protocols and ethics submission.
CB contributed to writing of the ethics, over all protocol design and its
compliance with GCP. MI, SE, OMK and TT contributed to the design of the
clinical protocol, ethics submission and manuscript composition. TTH was the
main author, contributed to the design of the overall protocol and ethics
submission. MJP-C contributed to the design of the overall protocol, design of
the assays, ethics submission and writing the manuscript.
Funding This study was funded by the Wellcome Trust and Dainippon
Sumitomo Pharma Co Ltd, Osaka, Japan. Supported by: Dainippon Sumitomo
Pharma Co Ltd, Osaka, Japan National Institute of Healthcare Research (Grant
No: R3101002), NIHR Imperial Biomedical Research Centre (NIHR BMRC),
Imperial Academic Health Science Centre (AHSC), Imperial Centre for
Respiratory Infection (CRI, Grant No: 083567/Z/07/Z), Wellcome Trust
(Grant No: 083429/Z/07/Z).
Competing interests None.
Ethics approval West London National Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement We are happy to share all resorces and protocols
defined in this paper with others in the field or the larger scientific
community.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in
smoking-related mortality in the United States. N Engl J Med
2013;368:351–64.
2. Decramer M, Janssens W. Chronic obstructive pulmonary disease
and comorbidities. Lancet Respir Med 2013;1:73–83.
3. Strulovici-Barel Y, Omberg L, O’Mahony M, et al. Threshold of
biologic responses of the small airway epithelium to low levels of
tobacco smoke. Am J Respir Crit Care Med 2010;182:1524–32.
4. van der, Vaart H, Postma DS, Timens W, et al. Acute effects of
cigarette smoke on inflammation and oxidative stress: a review.
Thorax 2004;59:713–21.
5. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year
follow up study of the general population. Thorax 2006;61:935–9.
6. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%.
Lancet 2006;367:1216–19.
7. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction
and emphysema in chronic obstructive pulmonary disease. N Engl J
Med 2011;365:1567–75.
8. Brusselle GG, Joos GF, Bracke KR. New insights into the
immunology of chronic obstructive pulmonary disease. Lancet
2011;378:1015–26.
9. Churg A, Wright JL. Testing drugs in animal models of cigarette
smoke-induced chronic obstructive pulmonary disease. Proc Am
Thorac Soc 2009;6:550–2.
10. Walters MJ, Paul-Clark MJ, McMaster SK, et al. Cigarette smoke
activates human monocytes by an oxidant-AP-1 signaling pathway:
implications for steroid resistance. Mol Pharmacol 2005;68:1343–53.
11. Oltmanns U, Chung KF, Walters M, et al. Cigarette smoke induces
IL-8, but inhibits eotaxin and RANTES release from airway smooth
muscle. Respir Res 2005;6:74.
12. Karimi K, Sarir H, Mortaz E, et al. Toll-like receptor-4 mediates
cigarette smoke-induced cytokine production by human
macrophages. Respir Res 2006;7:66.
13. Birrell MA, Wong S, Catley MC, et al. Impact of tobacco-smoke on
key signaling pathways in the innate immune response in lung
macrophages. J Cell Physiol 2008;214:27–37.
14. Wang JH, Kim H, Jang YJ. Cigarette smoke extract enhances
rhinovirus-induced toll-like receptor 3 expression and interleukin-8
secretion in A549 cells. Am J Rhinol Allergy 2009;23:e5–9.
15. Pace E, Ferraro M, Siena L, et al. Cigarette smoke increases
Toll-like receptor 4 and modifies lipopolysaccharide-mediated
responses in airway epithelial cells. Immunology 2008;124:401–11.
16. Paul-Clark MJ, Sorrentino R, Bailey LK, et al. Gram-positive and
Gram-negative bacteria synergize with oxidants to release CXCL8
from innate immune cells. Mol Med 2008;14:238–46.
17. Wright WR, Parzych K, Crawford D, et al. Inflammatory
transcriptome profiling of human monocytes exposed acutely to
cigarette smoke. PLoS ONE 2012;7:e30120.
18. Marwick JA, Wallis G, Meja K, et al. Oxidative stress modulates
theophylline effects on steroid responsiveness. Biochem Biophys
Res Commun 2008;377:797–802.
19. Silverman EK, Palmer LJ, Mosley JD, et al. Genomewide linkage
analysis of quantitative spirometric phenotypes in severe early-onset
chronic obstructive pulmonary disease. Am J Hum Genet
2002;70:1229–39.
20. Vulimiri SV, Misra M, Hamm JT, et al. Effects of mainstream
cigarette smoke on the global metabolome of human lung epithelial
cells. Chem Res Toxicol 2009;22:492–503.
21. Spira A, Beane J, Pinto-Plata V, et al. Gene expression profiling of
human lung tissue from smokers with severe emphysema. Am J
Respir Cell Mol Biol 2004;31:601–10.
22. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the
human airway epithelial cell transcriptome. Proc Natl Acad Sci USA
2004;101:10143–8.
23. Spira A, Schembri F, Beane J, et al. Impact of cigarette smoke on
the normal airway transcriptome. Chest 2004;125(5 Suppl):115S.
24. Heguy A, O’Connor TP, Luettich K, et al. Gene expression profiling
of human alveolar macrophages of phenotypically normal smokers
and nonsmokers reveals a previously unrecognized subset of genes
modulated by cigarette smoking. J Mol Med (Berl) 2006;84:318–28.
25. Halappanavar S, Russell M, Stampfli MR, et al. Induction of the
interleukin 6/ signal transducer and activator of transcription pathway
in the lungs of mice sub-chronically exposed to mainstream tobacco
smoke. BMC Med Genomics 2009;2:56.
26. Schadt EE. Molecular networks as sensors and drivers of common
human diseases. Nature 2009;461:218–23.
27. Lo Tam Loi AT, Hoonhorst SJ, Franciosi L, et al. Acute and chronic
inflammatory responses induced by smoking in individuals
susceptible and non-susceptible to development of COPD: from
specific disease phenotyping towards novel therapy. Protocol of a
cross-sectional study. BMJ Open 2013;3.
28. Woodruff PG. Novel outcomes and end points: biomarkers in chronic
obstructive pulmonary disease clinical trials. Proc Am Thorac Soc
2011;8:350–5.
8 Ross CL, et al. BMJ Open 2015;5:e005750. doi:10.1136/bmjopen-2014-005750
Open Access
29. Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic
biomarkers for asthma and chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2011;183:1633–43.
30. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive
pulmonary disease phenotypes: the future of COPD. Am J Respir
Crit Care Med 2010;182:598–604.
31. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-points
(ECLIPSE). Eur Respir J 2008;31:869–73.
32. Singh D, Edwards L, Tal-Singer R, et al. Sputum neutrophils as a
biomarker in COPD: findings from the ECLIPSE study. Respir Res
2010;11:77.
33. MacNee W, Rennard SI, Hunt JF, et al. Evaluation of exhaled breath
condensate pH as a biomarker for COPD. Respir Med
2011;105:1037–45.
34. Hillas G, Loukides S, Kostikas K, et al. Biomarkers obtained by
non-invasive methods in patients with COPD: where do we stand,
what do we expect? Curr Med Chem 2009;16:2824–38.
35. Hurst JR. Upper airway. 3: Sinonasal involvement in chronic
obstructive pulmonary disease. Thorax 2010;65:85–90.
36. Hakansson K, Konge L, Thomsen SF, et al. Sinonasal inflammation
in COPD: a systematic review. Eur Respir J 2013;42:1402–11.
37. Hurst JR, Wilkinson TM, Donaldson GC, et al. Upper airway
symptoms and quality of life in chronic obstructive pulmonary
disease (COPD). Respir Med 2004;98:767–70.
38. Hurst JR, Kuchai R, Michael P, et al. Nasal symptoms, airway
obstruction and disease severity in chronic obstructive pulmonary
disease. Clin Physiol Funct Imaging 2006;26:251–6.
39. Caillaud D, Chanez P, Escamilla R, et al. Association of chronic nasal
symptoms with dyspnoea and quality-of-life impairment in chronic
obstructive pulmonary disease. Respirology 2014;19:346–52.
40. Hurst JR, Wilkinson TM, Perera WR, et al. Relationships among
bacteria, upper airway, lower airway, and systemic inflammation in
COPD. Chest 2005;127:1219–26.
41. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and
lower airway inflammation at exacerbation of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2006;173:71–8.
42. Nicola ML, Carvalho HB, Yoshida CT, et al. Young “healthy”
smokers have functional and inflammatory changes in the nasal and
the lower airways. Chest 2014;145:998–1005.
43. Chanez P, Vignola AM, Vic P, et al. Comparison between nasal and
bronchial inflammation in asthmatic and control subjects. Am J
Respir Crit Care Med 1999;159:588–95.
44. American Thoracic Society Workshop. Immunobiology of asthma
and rhinitis. Pathogenic factors and therapeutic options. Am J Respir
Crit Care Med 1999;160(5 Pt 1):1778–87.
45. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin
Immunol 2004;114(5 Suppl):S135–8.
46. Chawes BLK, Edwards MJ, Shamji B, et al. A letter to the editor:
a novel method for assessing unchallenged levels of mediators in
nasal epithelial lining fluid. J Allergy Clin Immunol 2010;125:1387–9.
47. Folsgaard NV, Chawes BL, Rasmussen MA, et al. Maternal atopic
skewing of the neonatal nasal cytokine signature. Am J Resp Crit
Care Med 2011:275–80.
48. Nicholson GC, Kariyawasam HH, Tan AJ, et al. The effects of an
anti-IL-13 mAb on cytokine levels and nasal symptoms
following nasal allergen challenge. J Allergy Clin Immunol
2011;128:800–7.
49. Nathan RA, Eccles R, Howarth PH, et al. Objective monitoring of
nasal patency and nasal physiology in rhinitis. J Allergy Clin
Immunol 2005;115(3 Suppl 1):S442–59.
50. Schadt EE, Friend SH, Shaywitz DA. A network view of disease and
compound screening. Nat Rev Drug Discov 2009;8:286–95.
51. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature
2008;455:1054–6.
52. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet
activation in patients with stable and acute exacerbation of COPD.
Thorax 2011;66:769–74.
53. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and
lung function in mild-to-moderate chronic obstructive pulmonary
disease. The lung health study. Am J Respir Crit Care Med
2000;161(2 Pt 1):381–90.
54. Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry,
metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009;
(192):29–60.
55. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18
concentrations and health outcomes in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2011;
183:1187–92.
56. Cheng DT, Kim DK, Cockayne DA, et al. Systemic soluble receptor
for advanced glycation endproducts is a biomarker of emphysema
and associated with AGER genetic variants in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2013;188:948–57.
57. Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE:
a review of COPD biomarkers. Thorax 2014;69:666–72.
58. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers
improve clinical prediction of mortality in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2012;185:1065–72.
59. Kim DK, Cho MH, Hersh CP, et al. Genome-wide association
analysis of blood biomarkers in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2012;186:1238–47.
60. Muller DC, Degen C, Scherer G, et al. Metabolomics using
GC-TOF-MS followed by subsequent GC-FID and HILIC-MS/MS
analysis revealed significantly altered fatty acid and phospholipid
species profiles in plasma of smokers. J Chromatogr B Analyt
Technol Biomed Life Sci 2014;966:117–26.
61. Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies
perturbations in amino acid metabolism that sub-classify patients
with COPD. Mol Biosyst 2012;8:3125–33.
62. Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects
biomarkers of protein degradation in COPD patients. Eur Respir J
2012;40:345–55.
63. Fens N, van der Schee MP, Brinkman P, et al. Exhaled breath
analysis by electronic nose in airways disease. Established issues
and key questions. Clin Exp Allergy 2013;43:705–15.
64. Qiu W, Cho MH, Riley JH, et al. Genetics of sputum gene
expression in chronic obstructive pulmonary disease. PLoS ONE
2011;6:e24395.
65. Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes
associated with spirometric and radiological disease severity in
COPD ex-smokers. Thorax 2011;66:489–95.
Ross CL, et al. BMJ Open 2015;5:e005750. doi:10.1136/bmjopen-2014-005750 9
Open Access
